Building up an investment case requires looking at a stock holistically. Today Iâve chosen to put the spotlight on Meridian Bioscience, Inc. (NASDAQ:VIVO) due to its excellent fundamentals in more than one area. VIVO is a notable dividend-paying company that has been able to sustain great financial health over the past. In the following section, I expand a bit more on these key aspects. If youâre interested in understanding beyond my broad commentary, read the full report on Meridian Bioscience here.
VIVO is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities. This indicates that VIVO has sufficient cash flows and proper cash management in place, which is a crucial insight into the health of the company. VIVO appears to have made good use of debt, producing operating cash levels of 0.69x total debt in the prior year. This is a strong indication that debt is reasonably met with cash generated.
VIVOâs profit levels are sufficient enough to reinvest and payout as dividends, which has exceeded the low-risk savings rate, adequately rewarding investors for taking on the risk of holding a stock over a riskless asset. However, it is important to remember that dividend yields are a function of stock prices and corporate profits, which can be volatile.
For Meridian Bioscience, Iâve put together three pertinent aspects you should further research:
To help readers see past the short term
volatility of the financial market, we aim to bring you a long-term
focused research analysis purely driven by fundamental data. Note
that our analysis does not factor in the latest price-sensitive
company announcements.
The author is an independent contributor and at the time of
publication had no position in the stocks mentioned. For errors
that warrant correction please contact the editor at
[email protected].